Gritstone Bio Q2 EPS $(0.31) Beats $(0.35) Estimate, Sales $1.96M Miss $2.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Gritstone Bio reported Q2 losses of $(0.31) per share, beating the analyst consensus estimate of $(0.35) by 11.43%. However, the company's quarterly sales of $1.96 million missed the analyst consensus estimate of $2.50 million by 21.80%. This represents a 64.27% decrease over sales of $5.47 million the same period last year.
August 09, 2023 | 9:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Gritstone Bio's Q2 earnings beat estimates but sales missed, indicating mixed performance.
Gritstone Bio's earnings per share beat estimates, which is positive for the stock. However, the significant miss on sales and the large year-over-year decrease could negatively impact the stock, leading to a neutral overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100